Skip to main content
. 2020 Apr 7;7(3):328–335. doi: 10.1016/j.gendis.2020.03.010

Figure 1.

Figure 1

Timeline of phase III clinical trials evaluating systemic therapies for unresectable or advanced hepatocellular carcinoma in the last decade. ORR, objective response rate, the proportion of partial response and complete response per RECIST v1.1 criteria, except for brivanib which was evaluated by mRECIST criteria. Note that donafenib was also studied in a phase III trial, but the ORR was not reported.